相关实验视频

Updated: May 23, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

异常的PLAC8表达特征是质母细胞瘤具有temozolomide耐药性和一个免疫抑制的微环境

Han She¹, Tian-Ran Li², Guozhi Zhao³

¹Department of Anesthesiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400042, China.

|May 21, 2025

概括

胎盘特异性8 (PLAC8) 被确定为质母细胞瘤 (GBM) 中temozolomide耐药性的关键驱动因素. 向PLAC8可以克服耐药性,并改善IDH野生型GBM患者的免疫治疗反应.

科学领域:

神经瘤学神经瘤学
癌症生物学癌症生物学
分子医学是分子医学.

背景情况:

异酸脱酶野生型 (IDH-WT) 质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
泰莫佐洛米德 (TMZ) 是标准化疗,但耐药性限制了其有效性.
确定新的治疗点和生物标志物对于改善GBM治疗结果至关重要.

研究的目的:

调查胎盘特异性8 (PLAC8) 在IDH-WT GBM中TMZ耐药性的作用.
评估PLAC8作为GBM治疗的预后和预测生物标志物.
阐明PLAC8影响GBM对TMZ和免疫治疗敏感性的机制.

主要方法:

在GBM患者队列和细胞系中分析PLAC8表达.
PLAC8水平与临床结果,瘤等级和生存率的相关性.
通过涉及AKT-mTOR通路的机理学研究,研究PLAC8在TMZ敏感性中的作用.
对PLAC8与免疫细胞透和免疫疗法生物标志物相关性的生物信息和临床分析.

主要成果:

升高的PLAC8表达与较差的生存率和更高的GBM瘤等级有关,作为一个独立的预后因素.
在耐TMZ的GBM细胞和患者中,PLAC8被上调,这表明它作为耐药性的生物标志物具有潜力.
PLAC8通过AKT-mTOR信号通路调节TMZ的敏感性.
PLAC8表达与增加的免疫细胞透,免疫抑制瘤微环境和改变的免疫治疗生物标志物相关.

结论:

PLAC8是IDH-WT GBM中TMZ抗性的新型调解者.
PLAC8 是一个有前途的预后生物标志物,也是克服化疗抵抗的潜在治疗标.
PLAC8对瘤免疫微环境的调节表明它作为免疫疗法反应的预测生物标志物的实用性.
针对PLAC8为GBM提供了个性化治疗方法的潜在策略.

关键词:

在PLAC8中,你会看到PLAC8.TMZ 阻力阻力 TMZ 阻力质母细胞瘤是一种质母细胞瘤.免疫透免疫透是什么?免疫疗法免疫疗法

更多相关视频

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...